Youcare Pharmaceutical (SH:688658)2025-02-27 08:45Financial Performance - In 2024, the total operating revenue of Yuekang Pharmaceutical was RMB 378,087.60 million, a decrease of 9.90% compared to the previous year[4] - The operating profit for 2024 was RMB 15,906.29 million, down 31.37% year-on-year[4] - The net profit attributable to the parent company was RMB 12,371.70 million, reflecting a decline of 33.05% compared to the previous year[4] - The basic earnings per share decreased to RMB 0.28, down 31.71% from RMB 0.41 in the previous year[4] Assets and Equity - The total assets at the end of 2024 were RMB 573,811.24 million, a decrease of 2.93% from the beginning of the year[6] - The equity attributable to the parent company was RMB 357,763.00 million, down 0.28% from the beginning of the year[6] Research and Development - The company increased its R&D expenses as a percentage of operating revenue, impacting net profit[7] Sales Strategy - Adjustments to the sales strategy and pricing of the "Ginkgo Leaf Extract Injection" led to reduced sales revenue and profit contribution in Q4 2024[7] Asset Management - The company made provisions for asset impairment based on cautious principles regarding unreceived goods[7] Financial Data Disclaimer - Investors are advised to note that the financial data is preliminary and subject to final audit in the annual report[2]